Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06343038 |
Title | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS) |
Acronym | PROGNOSTICS |
Recruitment | Recruiting |
Gender | male |
Phase | Phase I |
Variant Requirements | No |
Sponsors | University Hospital, Basel, Switzerland |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | CHE |